A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of 12-Week Administration Of PF-00734200 To Subjects With Type 2 Diabetes Mellitus And Insufficient Glycemic Control On Metformin Treatment.
Phase of Trial: Phase II
Latest Information Update: 24 Dec 2013
At a glance
- Drugs Gosogliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Pfizer
- 31 Aug 2018 Biomarkers information updated
- 28 Mar 2012 Additional trial location added as reported by European Clinical Trials Database.
- 01 Feb 2011 Actual end date changed from Sep 2008 to Aug 2008 as reported by ClinicalTrials.gov.